N/A
Completed N=10
Effectiveness of rTMS on Pain and Quality of Life in Patients With Cancer Neuropathic Pain. Clinical Trial.
Source: ClinicalTrials.gov NCT05480410 ↗Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcomePrimary: Effect of Change of 20 rTMS Sessions on Pain — 5.53; 1.60; 1.97; 3.48 score on a scale
Summary
The purpose of this study is to evaluate the effectiveness of Repetitive transcranial magnetic stimulation (rTMS) on pain and quality of life in patients with cancer neuropathic pain.
Although there are currently different therapeutic options for neuropathic pain, most are limited or restricted to pharmacotherapy. Transcranial magnetic stimulation (TMS) is a tool recently incorporated into neuroscience in the management of neuropathic cancer pain.
The study will include 10 patients with oncologic neuropathic pain who will receive 20 sessions of rTMS and the effect on pain and quality of life.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Effect of Change of 20 rTMS Sessions on Pain |
5.53; 1.60; 1.97; 3.48 | — |
| PRIMARY Effect of Change of 20 rTMS Sessions on Pain and Functionality |
5.53; 1.60; 1.97; 3.48; 5.75; 0.73 | — |
| SECONDARY Effect of Change of 20 rTMS Sessions on Quality of Life |
68.90; 91.00; 85.10; 79.50 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with neuropathic pain of oncological origin
- Patients of legal age (18 years old)
- Patients using their cognitive faculties
Exclusion Criteria
- Pregnancy
- History of negative reaction to TMS
- History of seizure, history of epilepsy stroke, brain surgery and cranial metal implants.
Data sourced from ClinicalTrials.gov (NCT05480410). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.